Navigating Medi-Cal Aimovig Prior Authorization with Klivira

Successfully managing Medi-Cal Aimovig prior authorization is critical for ensuring patient access to this essential migraine therapy. Klivira streamlines the complex requirements, improving efficiency and reducing administrative burden.

Revenue cycle directors and prior authorization coordinators face significant challenges when processing specialty medication PAs, especially for state Medicaid programs like Medi-Cal. Understanding the specific criteria for drugs like Aimovig (erenumab) is paramount to minimizing delays and denials, directly impacting patient care and your clinic's financial health.

Aimovig (Erenumab): Indications and Medi-Cal Context

Aimovig (erenumab) is a CGRP receptor antagonist indicated for the preventive treatment of chronic and episodic migraine. As a specialty medication, its coverage under Medi-Cal, California's Medicaid program, necessitates a robust prior authorization (PA) process. Patients typically considered for Aimovig have experienced frequent and debilitating migraines, often after failing conventional preventive therapies.

Medi-Cal's Prior Authorization Requirements for Aimovig

Medi-Cal, administered by the California Department of Health Care Services (DHCS), typically implements specific formulary guidelines and step therapy requirements for CGRP antagonists like Aimovig. Providers should anticipate demonstrating that the patient has tried and failed, or has a contraindication to, a defined number of alternative preventive migraine treatments before Aimovig will be approved. Documentation of migraine frequency and severity is also a standard requirement.

Common Denial Reasons for Aimovig Under Medi-Cal

Denials for Medi-Cal Aimovig prior authorization often arise from insufficient clinical documentation, particularly regarding the failure of prior step therapy medications. Other common reasons include incorrect or incomplete ICD-10 coding, lack of detailed patient history supporting the diagnosis of chronic or episodic migraine, or administrative errors in the submission process. Understanding these pitfalls is crucial for a successful initial submission.

Navigating the Medi-Cal Appeal Pathways for Erenumab

When an Aimovig PA is denied by Medi-Cal, providers have the right to appeal. The appeal process typically involves submitting additional clinical information, a detailed letter of medical necessity from the prescribing physician, and any further diagnostic test results. Adhering to Medi-Cal's strict timelines for reconsideration and ensuring all submitted documentation directly addresses the denial reason are critical steps.

Streamlining Aimovig Prior Authorizations with Klivira

Klivira's platform automates the complex Medi-Cal Aimovig prior authorization workflow, integrating with your EMR and payer portals. Our solution helps identify specific Medi-Cal requirements, compile necessary clinical data, and manage submission and tracking, significantly reducing manual effort and accelerating patient access to erenumab. This automation minimizes the administrative burden on your PA coordinators and improves overall revenue cycle efficiency.

Key Documentation for Medi-Cal Aimovig PA Submissions

Patient demographics and Medi-Cal identification number.
ICD-10 codes for chronic or episodic migraine (e.g., G43.109, G43.009).
Detailed clinical notes documenting migraine frequency, severity, and impact on daily activities.
Evidence of prior trial and failure (or contraindication) of at least two other classes of preventive migraine therapies (e.g., beta-blockers, tricyclic antidepressants, anticonvulsants).
Prescriber's NPI, DEA, and contact information.
Any relevant diagnostic test results or specialist consultation reports.

Frequently asked questions

What is the typical step therapy requirement for Aimovig under Medi-Cal?

Medi-Cal generally requires documentation of failure or contraindication to a specified number of alternative, often generic, preventive migraine therapies before approving Aimovig. These typically include medications from different pharmacological classes commonly used for migraine prophylaxis.

How does Klivira help with Medi-Cal Aimovig PA submissions?

Klivira automates the entire prior authorization workflow for Medi-Cal Aimovig, from identifying specific payer rules and gathering required clinical data from your EMR to submitting and tracking the PA. This reduces manual tasks, minimizes errors, and accelerates approval times.

What are common reasons for Aimovig PA denials by Medi-Cal?

Common denial reasons include insufficient documentation of prior failed therapies, lack of detailed clinical notes supporting migraine diagnosis and severity, or submission errors. Ensuring all Medi-Cal specific criteria are met and accurately documented is crucial.

Can Klivira integrate with our EMR for Medi-Cal Aimovig prior authorizations?

Yes, Klivira is designed for seamless integration with major EMR systems using standards like SMART on FHIR. This allows for automated data extraction and population of PA forms, significantly streamlining the Medi-Cal Aimovig prior authorization process.

What should be included in an appeal for a denied Medi-Cal Aimovig PA?

An appeal should include a comprehensive letter of medical necessity, additional clinical documentation addressing the specific reason for denial, and any new supporting evidence. Adhering to Medi-Cal's appeal timelines and procedural requirements is essential.